Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426946 | 1.00 | HSD17B2 (0.49) | HSD17B2TSHRCASP1ESR1MEN1 | |
| Cyanate SCHEMBL29116701 | 0.90 | HSD17B2 (0.43) | HSD17B2TSHRCASP1ESR1MEN1 | |
| SCHEMBL15171112 | 0.84 | ESR1 (0.48) | HSD17B2TSHRCASP1ESR1MEN1 | |
| Methacrylic Acid SCHEMBL29724200 | 0.84 | HSD17B2 (0.46) | HSD17B2MEN1KMT2ATAS2R14ALDH1A1 | |
| SCHEMBL172788 | 0.84 | ESR1 (0.64) | ESR1MEN1KMT2AARESR2 | |
| SCHEMBL13303116 | 0.83 | ESR1 (0.50) | HSD17B2TSHRCASP1ESR1ACHE | |
| Hydrochloric Acid SCHEMBL27419116 | 0.82 | ESR1 (0.61) | ESR1MEN1KMT2AARESR2 | |
| SCHEMBL22000814 | 0.81 | ESR1 (0.45) | HSD17B2TSHRCASP1ESR1MEN1 | |
| SCHEMBL1755260 | 0.80 | PDE2A (0.46) | TSHRTAS2R14ALDH1A1KIF11MAPT | |
| SCHEMBL674323 | 0.79 | ALDH1A1 (0.67) | TSHRCASP1ESR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | claimed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | claimed |
| JP-8217863-A | — | — | None | — | — | JP | disclosed |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| EP-4562009-A1 | NOVEL COMPOUNDS | AC Immune SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| EP-4511114-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12139471-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2024-11-12 | — | — | US | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-20240101563-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2024-03-28 | — | — | US | disclosed |
| WO-2024023266-A1 | NOVEL COMPOUNDS | AC IMMUNE SA (CH) | 2024-02-01 | — | — | WO | disclosed |
| US-9023584-B2 | Radiation-sensitive composition, and compound | JSR CORPORATION (JP) | 2015-05-05 | — | — | US | disclosed |
| WO-2015035032-A1 | BICYLIC COMPOUNDS AS MODULATORS OF RORGAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-12 | — | — | WO | disclosed |
| US-20150057271-A1 | DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS | AMGEN INC. | 2015-02-26 | — | — | US | disclosed |
| US-20130280658-A1 | RADIATION-SENSITIVE COMPOSITION, AND COMPOUND | JSR CORPORATION (JP) | 2013-10-24 | — | — | US | disclosed |
| EP-2460799-A1 | NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION | FUJIFILM Corporation (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2004653-B1 | 3-SUBSTITUTED N-(ARYL- OR HETEROARYL)-PYRAZO[1,5-A]PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-12-30 | — | — | EP | disclosed |
| JP-H08217863-A | POLYARYLATE AND ELECTROPHOTOGRAPHIC SENSITIVE MATERIAL PRODUCED BY USING THE POLYARYLATE | UNITIKA LTD | 1996-08-27 | — | — | JP | disclosed |
| EP-0491326-A2 | Process for the functionalization of trifluoromethylbenzenes | ISTITUTO GUIDO DONEGANI S.p.A. (IT) | 1992-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057271-A1 | DIHYDROBENZOXAZINE AND TETRAHYDROQUINOXALINE SODIUM CHANNEL INHIBITORS | SCN5A, KCNH1, KCNQ5 | HSD17B2 2653/4885TSHR 4670/4885CASP1 1755/4885 |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | HSD17B2 1014/4885TSHR 1731/4885CASP1 749/4885 |
| US-20240101563-A1 | NOVEL COMPOUNDS | NLRP3, NOD1, NLRP1 | HSD17B2 934/4885TSHR 3748/4885CASP1 10/4885 |
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | HSD17B2 219/4885TSHR 1023/4885CASP1 3346/4885 |
| US-12139471-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | HSD17B2 2395/4885TSHR 2465/4885CASP1 7/4885 |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | HSD17B2 2395/4885TSHR 2465/4885CASP1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.